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Abstract
Plasmodium vivax has the ability to relapse from dormant parasites in the liver weeks or
months after inoculation, causing further blood-stage infection and potential onward trans-
mission. Estimates of the force of blood-stage infections arising from primary infections and
relapses are important for designing intervention strategies. However, in endemic settings
their relative contributions are unclear. Infections are frequently asymptomatic, many indi-
viduals harbor multiple infections, and while high-resolution genotyping of blood samples
enables individual infections to be distinguished, primary infections and relapses cannot be
identified. We develop a model and fit it to longitudinal genotyping data from children in
Papua New Guinea to estimate the incidence and seasonality of P vivax primary infection
and relapse. The children, aged one to three years at enrolment, were followed up over 16
months with routine surveys every two months. Blood samples were taken at the routine vis-
its and at other times if the child was ill. Samples positive by microscopy or a molecular
method for species detection were genotyped using high-resolution capillary electrophore-
sis for P vivax MS16 andmsp1F3, and P falciparummsp2. The data were summarized as
longitudinal patterns of success or failure to detect a genotype at each routine time-point
(eg 001000001). We assume that the seasonality of P vivax primary infection is similar to
that of P falciparum since they are transmitted by the same vectors and, because P falcipa-
rum does not have the ability to relapse, the seasonality can be estimated. Relapses occur-
ring during the study period can be a consequence of infections occurring prior to the study:
we assume that the seasonal pattern of primary infections repeats over time. We incorpo-
rate information from parasitological and entomology studies to gain leverage for estimating
the parameters, and take imperfect detection into account. We estimate the force of P vivax
primary infections to be 11.5 (10.5, 12.3) for a three-year old child per year and the mean
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number of relapses per infection to be 4.3 (4.0, 4.6) over 16 months. The peak incidence of
relapses occurred in the two month interval following the peak interval for primary infections:
the contribution to the force of blood-stage infection from relapses is between 71% and 90%
depending on the season. Our estimates contribute to knowledge of the P vivax epidemiol-
ogy and have implications for the timing of intervention strategies targeting different stages
of the life cycle.
Author Summary
Plasmodium vivax is the most widespread of the malaria species affecting humans. It has
the ability for parasites to lie dormant in liver cells and then to relapse weeks or months
later, causing further blood-stage infections and onward transmission. Relapses present a
challenge to control and elimination programs. The contribution of relapses to the force of
blood-stage infection is not well established. While genotyping can distinguish individual
infections, the difficulty lies in the inability to distinguish primary infections (occurring
shortly after an infectious mosquito bite) and relapses. This is a gap in the knowledge of
the epidemiology of P vivax. We develop a statistical model to tease out and estimate the
contributions of primary infections and relapses to the force of blood-stage infection. We
use data from a cohort of children in Papua New Guinea with genotyped routine blood
samples. The study area has both P vivax and P falciparummalaria: we use the seasonality
of P falciparum to estimate the seasonality of P vivax primary infections. We also take into
account infections occurring prior to the study period and their subsequent relapses dur-
ing the study period. We find that approximately 80% of the force of blood-stage infection
l is contributed by relapses and that primary infections and relapses have different seasonal
patterns. The findings are important to the epidemiology of P vivax and for designing
intervention strategies targeting different stages of the parasite life cycle.
Introduction
Globally, over a billion inhabitants are exposed to Plasmodium vivax and suffer from an esti-
mated 70 to 80 million cases per year [1]. It has been increasingly recognized that P vivax can
cause severe and fatal disease [2,3]. Effective control measures are needed. Designing interven-
tion strategies requires estimates of the incidence of blood-stage infection from both primary
infection and relapses resulting from the ability of P vivax to remain dormant in liver cells for
weeks or months. However, these processes, and the longitudinal patterns they give rise to,
have not been well quantified in natural populations.
The timing of relapses varies by geographic region although the triggers have not been
established [4]. Information on the patterns of relapse have come from studies of the deliberate
infection of non-immune adult neurosyphilis patients and healthy volunteers, clinical episodes
in travellers and soldiers returning from endemic areas and primaquine studies [4,5]. Most of
these studies assume that in individuals with little immunity, relapses will cause symptoms, but
this has not been established. Few data are available to date on infection in children and adults
living in endemic areas who are likely to have acquired some immunity and may harbour mul-
tiple P vivax infections.
Cohort studies in natural populations provide a source of information on P vivax infection
dynamics. The infecting genotypes can be distinguished on the basis of highly polymorphic
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genetic markers. However, the analysis of such data is not straightforward because the detec-
tion of genotypes is imperfect, even when using polymerase chain reaction (PCR). Several
methods have been developed to estimate P falciparum infection, clearance, duration of infec-
tions and detectability [6–11]. P vivax presents additional challenges due to the relapses, which
cannot be distinguished from the primary infections by genotyping [12].
We present estimates of the relative contributions of primary infection and relapses to the
force of blood-stage infection in a cohort of children in Papua New Guinea aged one to five
years [13], for the first time estimating these quantities in a cohort without primaquine treat-
ment. The analyses indicate how these relative contributions vary seasonally, allowing for age,
detectability, treatment and insecticide-treated net (ITN) use. Previous studies have summa-
rized the observed parasitology and clinical incidence [13], the force of blood-stage infection
[14], the detectability [15], and described the multiplicity of infection [16] in this cohort. To
disentangle the contributions of primary infection and relapse, we use this information and
gain additional leverage for estimating the parameters from complementary entomology stud-
ies and experimental and therapeutic infections.
Methods
Study design, sample collection and genotyping
The cohort study was carried out in Ilaita, Maprik district, Papua New Guinea. Two hundred
and sixty-four children aged between one and three years at enrolment were followed up over
16 months [13]. The prevalence by light microscopy at enrolment was 44% for P vivax and
33% for P falciparum, with an estimated 2.46 P vivax and 2.56 P falciparum episodes per child
per year [13].
Finger prick blood samples were collected for genotyping at nine routine survey time-points
at two-month intervals. The first and last surveys comprised single blood samples whereas at
the second to eighth routine time-points, two samples were taken 24 hours apart. Additionally,
blood samples were taken if the child was ill, either when presenting for treatment or during
fortnightly active case detection visits. Coartem was provided by the study team to those who
were RDT positive and had fever or history of fever in the last 48 hours. Further antimalarial
drugs were provided outside the study and were recorded in the child’s health book.
DNA was extracted as described previously [15]. High-resolution genotyping by PCR fol-
lowed by capillary electrophoresis was carried out for one P falciparummarker, merozoite sur-
face protein 2 (msp2), and two P vivaxmarkers (msp1F3 and MS16). The methods have been
described elsewhere [16,17]. Only blood samples positive for P falciparum or P vivax by
microscopy or by post-PCR ligase detection reaction (LDR), a molecular method for Plasmo-
dium species detection [18], were genotyped. This was justified by the very low proportion of
negative samples which were positive by genotyping [16].
Ethics statement
The cohort study was approved by institutional review boards of the PNGMedical Research
Advisory Committee (approvals 05.19 and 09.24), University Hospitals Case Medical Center
(Cleveland, Ohio USA), and the Ethikkommission beider Basel (approval 03/06). Informed
written consent was provided by the parents or legal guardians of each child.
Data preparation
For the observed data, we denote an observed genotype as 1 and an undetected or absent geno-
type as 0. For the 9 time-points, there are 512 possible patterns which were numbered from 0
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to 511 using their binary value (eg 000000100 is pattern 4). This yielded a frequency distribu-
tion of binary patterns for each child, to which statistical models could be fitted (Fig 1). We
restricted the analysis to participants who provided a blood sample on at least one day at each
of six or more routine time-points. Where treatment was given following the first visit of a rou-
tine 24 hour pair, the second visit was excluded.
Blood samples were also collected and genotyped if a child was ill at non-routine visits. In
the analysis, we assigned genotypes from visits prompted by illness to the next routine time-
point (we define month intervals to start just after the routine time-point). Correspondingly,
we include the treatment but timed to occur just after the routine time-point. This is equiva-
lent to assuming that the blood-stage infection would have persisted up to this time-point in
the absence of treatment. This may cause some detection bias since clinical symptoms for
malaria are more likely in those with less acquired immunity and because seeking treatment
for both malaria and other illnesses is associated with distance to the health facility. However
excluding these genotypes would also cause bias since, in most cases, they were treated and
the genotypes would not be present at the next routine time-point. The bias may increase the
estimated incidences.
The model does not allow for reinfection of a child with the same genotype. For the analysis
of MS16, this was justified by the low frequencies of most alleles, with the most common allele
at baseline in this cohort having a frequency of only 5% compared with 24% for the most fre-
quent allele of P vivaxmsp1F3 and 15% for P falciparum msp2 [16,19]. For this reason the pri-
mary analysis (including estimates of the force of infection) of P vivax focuses on the marker
MS16. For P vivax msp1F3 we report the sensitivity of the estimates to the exclusion of the four
Fig 1. Example of the structure of the data. The diagram represents the data for a child who had no missing visits. The time of the routine visits is shown by
red triangles: the timepoints were spaced two months apart with two visits 24 hours apart for all but the first and last timepoints. The child had had a sample
taken at each routine visit. Eighteen distinct genotypes were detected, each is shown with blue rectangles representing the visits where the genotypes where
detected. The timing of an illness visit (light blue rectangle) and recorded treatments (dark blue rectangle) is shown below. The column for observed patterns
shows how the data are represented for the analysis: 0 indicates that the genotype was not detected at that routine time-point and 1 that it was detected. The
pairs of routine visits 24 hours apart were combined, and the detectability was taken into account. The observed pattern ID is the distinct number assigned to
the specific pattern.
doi:10.1371/journal.pntd.0004582.g001
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most common alleles We omit alleles with frequencies greater than 5% from analyses of the
seasonality of P falciparum msp2.
The seasonality of P vivax primary infections is estimated from the
seasonality of P falciparum infections
We assume that the seasonal pattern of P falciparum infections provides approximate estimates
of the seasonal pattern of P vivax primary infections since (i) P vivax and P falciparum are
transmitted by the same vectors and (ii) we assume that seasonality is driven primarily by vec-
tor densities and that parasites in the human host are less important. The validity of this
assumption was investigated using entomological and parasitological data from the Wosera,
Papua New Guinea (S1 Text).
Thus models for both P vivax and P falciparum are required. We describe the general struc-
ture of these models followed by their specific features.
General structure of the models for infection dynamics
We use Markov models to estimate the infection dynamics. The processes determining the
modelled frequencies of the binary patterns of the genotypes are acquisition (via primary infec-
tion or relapse), clearance of the blood-stage infections and detection.
Following [6,8,9], each genotype, occurring in each child, can be present or absent at each of
the 9 routine study time-points leading to 29(512) possible true patterns. The true patterns are
denoted by tcs for child c and pattern s = 0,. . .,511. The probability of a particular true pattern,
Pr(tcs) may vary between children due to covariates such as treatment, age and ITN use.
The state of the genotype at each time-point i, whether 1 or 0, is denoted by dcsi. The proba-
bility of each true pattern, Pr(tcs), is the product of the probability of the states at each time-
point, PrðtcsÞ ¼
Y
i
PrðdcsiÞ: The probability of the initial state is estimated as a parameter and
the transition probabilities for each two month period are derived from the parameters for
clearance and infection for the speciﬁc model (described in later sections) using equations
fromMunch [20].
Once the probabilities of the true patterns have been calculated, we then take detectability
into account to obtain the probability of each observed pattern ocw for child c and pattern
w = 0,. . .511. The probability of detecting a genotype given that it is present at time-point i in
child c, zci, depends on the probability of detecting the genotype in a single blood sample, (qg
for samples which were genotyped because they were microscopy or LDR positive and qk for
samples which were negative and not genotyped), and the corresponding numbers of blood
samples gci and kci,
zci ¼ 1 ðð1 qgÞgci ð1 qkÞkciÞ:
We fix the value of qg to previous estimates from this cohort obtained from an analysis of
the samples taken 24 hours apart [15]: 0.79 (0.76, 0.82) for P falciparum msp2, 0.61 (0.58, 0.63)
for P vivaxMS16 and 0.73 (0.71, 0.75) for P vivax msp1F3. Where two samples 24 hours apart
were both genotyped and combined for one routine timepoint, the probability of detecting a
genotype in at least one sample is estimated to be 1−(1−qg)
2, a special case of the equation
above. Since there was a very low proportion of samples negative by microscopy and LDR
which were found to be positive [16], we set qk to 0.99. Detectability has been found to vary by
age in cohorts spanning all ages [6, 9], however the variation is expected to be small over the
narrow age range in this cohort. We acknowledge that detectability may decrease with acquired
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immunity and vary between primary infections and relapses but we assume a constant for
these analyses.
The probability of observing pattern ocw conditional on the true pattern tcs, Pr(ocw | tcs), is
obtained by multiplying the probability of the true pattern by the probability of detection,
Prðocwj tcsÞ ¼ PrðtcsÞ
Y
i
f ðbcwi; dcsiÞ
where bcwi is the observed state at time-point i, and
f ðbcwi; dcsiÞ ¼
1 if bcwi ¼ 0 and dcsi ¼ 0
0 if bcwi ¼ 1 and dcsi ¼ 0
1 zci if bcwi ¼ 0 and dcsi ¼ 1
zci if bcwi ¼ 1 and dcsi ¼ 1
8>><
>>:
The probability of observed pattern, Pr(ocw), is given by summing over the conditional
probabilities given each of the possible true patterns,
PrðocwÞ ¼
X511
s¼0
Prðocw j tcsÞ PrðtcsÞ s ¼ 0; . . . :511
We assume a multinomial distribution for the frequency of the observed patterns nc0, nc1, . . ...
nc511 ~Mn(N, Pr(oc0), Pr(oc1), . . . . . . Pr(oc511)) whereN is the number of possible genotypes per
child, which is taken from the number of observed genotypes for all children in the cohort.
The log likelihood (LL) is given by
LL ¼
XC
c¼1
X511
w¼0
PrðocwÞncw
where ncw is the frequency of pattern w for child c and C is the number of children in the study.
Missing time-points were included since the number of visits at the time-point, and therefore
the detectability, was set to zero.
Estimating the seasonality of the incidence of P falciparum infections
Following earlier approaches [6,8,9], we assume that the observed P falciparum patterns must
be derived from a restricted set of true patterns which assume that negative routine time-points
bracketed by positive time-points are attributable to a lack of detection (this is not true for P
vivax due to relapses). Only the 143 children with at least one visit at each study time-point are
included in the P falciparum seasonality analysis. We allow the incidence of P falciparum infec-
tions to vary seasonally: for each interval leading up to time-point i, the incidence of infection
with a P falciparum genotype, λfci, was estimated.
The probabilities were derived for transitions from 0 to 1, and 1 to 0, via equations from
Muench [20],
p01fci ¼
lfci
lfci þ mf
1 eðlfci þ mf Þmci 
p01fci ¼
mf
lfci þ mf
1 eðlfci þ mf Þmci 
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where μf is the clearance rate for P falciparum infections, λfci is the mean infection rate for a P
falciparum genotype for child c in interval i andmci is the duration at risk in two-month units.
The probabilities p00fci and p
11
fci are given by 1 p01fci and 1 p10fci respectively.
Treatment was found to affect the seasonal pattern slightly and was included in the model.
We also adjusted for different biting rates by age using body surface area.
Model for P vivax infection dynamics
Acquisition of P. vivax blood-stage infection can be either by primary infection or relapse. Since
we assume that reinfection with the same genotype is negligible (as frequent alleles were
excluded in the case ofmsp1F3), it follows that the earliest blood-stage infection from a genotype
could be due to a primary infection or relapse and that subsequent infections of the same geno-
type must be due to relapses. The primary infection of a genotype relapsing during the study
period occurred either during the study period or before follow-up began. We take primary
infections occurring prior to the study into account by extending the numbers of time-points to
include eight notional pre-study two-monthly time-points, spanning the 16 months preceding
enrolment making a total number of notional pre-study and actual routine time-points of17.
We chose a period of 16 months for the pre-study period so that sufficient time was allowed for
the modelled primary infections to minimally constrain the subsequent relapses occurring dur-
ing the study period. The pre-study period timepoints are set two months apart since they must
capture the seasonality of the primary infections (which was estimated at two month intervals,
the spacing of timepoints during the study period). For a pre-study time-point before the child
was born, the probability of a genotype being present is set to zero.
The probability of a true P vivax genotype pattern is given by the probability that the pri-
mary infection occurred in interval y, pyc, for y = 0, . . .16, multiplied by the probabilities of the
subsequent transitions driven by clearance of blood-stage infections and relapses. We assume
that the primary infection always occurs soon after the inoculation, but may not necessarily be
detected or occur at the time of the routine time-point.
PrðtcsÞ ¼
Y
i
PrðdcsiÞ ¼ pyc
Y
i>y
PrðdcsiÞ
We estimate the seasonal pattern and magnitude of pyc.
The incidence of P vivax primary infections
The incidence of P vivax primary infection with a genotype in interval i is λvi = β1 λfi, where β1
represents a constant to calculate the number of P vivax primary infections based on the sea-
sonality of P falciparum infection. β1 is estimated. The seasonality was estimated for the
observed study period. It was assumed to repeat with an annual cycle and was extended back-
wards to the eight notional two-month intervals prior to the study period for the P vivax
model.
If the genotype has not been present up until interval i, then the probability of a primary
infection during interval i is 1 elvi mci and the probability that a primary infection does not
occur is elvi mci . Thus the probability that a primary infection occurs in interval y is
pyc ¼ ð1 elvycmciÞ
Qy1
i ¼ 1 e
lvycmci . We do not adjust pyc for treatment.
The clearance of P vivax blood-stage infections
We used a value for μb, the rate of clearance of untreated blood-stage infections, of 0.8 per two
month interval, corresponding to a mean duration of blood-stage infection of 76 days esti-
mated from malaria therapy patients (Ross et al, in prep). This value is consistent with an
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estimate from a different cohort in Papua New Guinea [21]. μb could not be reliably estimated
from the cohort data due to very frequent treatment of blood-stage infections. In the model, we
assume that a relapse does not affect the duration of an ongoing blood-stage infection with the
same genotype, and that the mean durations of blood-stage infections resulting from relapses
and primary infections are the same. Similarly, μb, does not change with age or acquired immu-
nity, based on findings in P falciparum [22].
Treatment was assumed to terminate the blood-stage infection. The child was assumed to
be at risk of a new blood-stage infection from 14 days after the last treatment to allow for the
prophylactic period. If there was an illness visit with P vivax genotypes detected and the geno-
types were combined with the following routine timepoint, then the treatment was assumed to
occur just after the subsequent routine timepoint.
The incidence of relapse by time since primary infection
We allow the incidence of relapse to vary by time after the primary infection. We treat relapses
as independent both between genotypes and within a genotype. The incidence of relapse is also
independent of the presence of blood-stage infection with the same genotype. Early relapses
may occur in the same two-month interval as the primary infection [23–25]. Primary infec-
tions are modelled as occurring half way through the interval.
γyci is the incidence of relapses in interval i conditional on the primary infection having
occurred in interval y for i−y = 1, . . .7. The transition probabilities are again derived from the
rates using the equations fromMuench [20],
p01yci ¼
giyc
giyc þ mb
1 eðgyci þ mbÞmci 
p10yci ¼
mb
gyci þ mb
1 eðgyci þ mbÞmci 
We initially tried to estimate the distribution of relapse times from the Papua New Guinea
cohort. However we were unable to robustly estimate the incidence of relapse in the interval in
which the primary infection occurs, probably since primary infections have a higher probabil-
ity of leading to clinical illness, and therefore being picked up during illness visits, and we
include genotypes from illness visits at the subsequent routine time-point with treatment after-
wards. We were also unable to robustly estimate the incidence of relapses between 12 and 16
months after the primary infection, probably due to insufficient data. We therefore constrained
the time-pattern of the incidence of relapses using data from Coatney et al [26] on the distribu-
tion of the incidence of relapse, f(x) (S2 Text). This distribution was consistent with the pattern
of our preliminary findings for months two to twelve. We estimate a parameter,β2, which acts
as a scale factor to obtain the absolute incidence of relapse so that γiyc = f(i−y) β2 in the absence
of covariates. A list of quantities in the model is given in S1 Table.
Covariates
We considered a limited number of covariates in the P vivaxmodel (Table 1).
Different assumptions about the effect of antimalarial treatment were possible. Coartem
was provided by the study team to those who were RDT positive and had fever and history of
fever. Treatment was also sought in the health centres and recorded in the health book. We
assumed that monotherapy with amodiaquine, chloroquine, SP and cotrimoxazole had negligi-
ble effects and did not include the small number of these as treatments. The majority of treat-
ments included were coartem or artesunate combinations (80%) and amodiaquine and
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sulphadoxine-pyrimethamine (AQ-SP, 20%). We assumed that these treatments resulted in a
parasitological cure. Where treatment was given following the first visit of a 24 hour pair, the
second visit was excluded. Small changes in the assumptions about treatment did not alter the
conclusions, however increasing the assumed prophylactic period did increase the estimated
incidence of relapse and to a lesser extent the estimated incidence of primary infection.
We also attempted to adjust the P vivax incidence of relapse for the presence of a P falcipa-
rum fever, any malaria fever, or any fever, in the previous interval.
Implementation
Wemaximised the exact log likelihood using the Nelder-Mead algorithm [29,30] comparing
the observed frequencies of patterns with the expected frequencies summed over all genotypes
and all children. Confidence intervals were calculated using profile likelihood [31,32]. The pro-
gram was written in C++.
Results
Descriptive summary of the Ilaita I cohort data
A total of 264 children were enrolled into the cohort, 189 at the time of the first survey. Routine
survey follow-up was high: on average 95% of those enrolled were present at each of the routine
visits[13]. Of the 264 enrolled, 243 (92%) were seen at least once at six or more routine study
time-points and 143 (54%) children were seen at least once at all nine routine time-points. The
children seen at least once at 6 or more routine time-points contributed a total of 2003 routine
time-points, 656 (33%) with one visit and 1347 (67%) with two visits 24 hours apart. There
were 1038 intervals which included visits made due to illness. Treatment was given during a
median of 4 intervals per child (range = 0,9).
There were 114 P vivaxMS16 alleles detected, the most common had a frequency of 5% in
the baseline survey. There were 63msp1F3 alleles, with the highest frequency of 24% and 55 P
falciparum msp2 with the highest frequency of 15% (Table 2). Omitting alleles which were
more frequent than 5% left us with 59msp1F3 and 50msp2 alleles. The lower numbers of
msp1F3 compared to MS16 genotypes (Table 2) suggests that the former locus is insufficiently
Table 1. Covariates included in the P vivaxmodel and their action.
Covariate Effect(s)
Age The rate of primary infection is scaled by body surface area, estimated using WHO growth
standards for weight and height[27] and the Mosteller formula [28]. Age is additionally a
potential covariate for the incidence of relapse (</36months). We assume no maternal
immunity on liver-stage parasites, nor prenatal infections.
Treatment Effective treatment is assumed to terminate all blood stage infections. The probability of a
genotype causing a new blood-stage infections at the subsequent routine time-point (a
transition of 0 to 1) is calculated using the time at risk from the end of the prophylactic
period to the routine timepoint Treatment is assumed not to affect the pre-erythrocytic
stages. If there was an illness visit with P vivax genotypes detected and the genotypes
were combined with the following routine timepoint, then the treatment was assumed to
occur just after the subsequent routine timepoint
ITN use Ratio for the incidence of primary infection. ITN use during the study period also applies to the
pre-study period1
Village Ratio for the incidence of primary infection in Sunuhu compared to Ilaita (regions within the
study area)
1There was no special ITN campaign in the pre-study or study periods
doi:10.1371/journal.pntd.0004582.t001
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polymorphic for the method to work well: many co-infections have the same allele as this
locus. This supports the use of P vivaxMS16 for the primary analysis. We also ran the analysis
with and without the frequent P vivax msp1F3 alleles.
To describe the observed longitudinal patterns, we summarize data from the 143 children
with at least one visit at each of the 9 routine study time-points.
There were 1837 P vivaxMS16 genotypes detected in 143 children with samples at each rou-
tine time-point: of the genotypes detected, 1283 (69%) were observed in one interval per child
(e.g. pattern 00010000), 389 (21%) in two intervals (e.g. pattern 01000100), 124 (7%) in three
and 41 (2%) in four or more. The maximum number of intervals in which an allele was
detected in an individual child was 7. The majority of these infections were detected through
the routine surveys only (1256, 68%) or both routine and sick visits (303, 16%) but 278 (15%)
genotypes were only seen at the sick visits. Genotypes detected more than once in a child, were
detected again most frequently in the intervals immediately following their first detection
(Table 3). Otherwise they tended to be present in one interval and not the next, consistent with
the high levels of treatment which truncates longer durations, or short durations of patent
blood-stage infections.
Results: Model estimates
Simulated data. To validate our method, we simulated data for specified parameter values
(S3 Text). The estimation procedure was able to recover the values reasonably well.
Ilaita I cohort. The estimated seasonal pattern for the force of infection for P falciparum
shows a peak in January 2007 (Fig 2a), in agreement with previous estimates by other methods
Table 2. Genotypes detected in 143 children with at least one blood sample at each routine time-
point.
Pf msp2 Pv MS16 Pv msp1F3
Number of genotypes per child, median (90% central range) 4 (1,11)* 12 (2,23) 1 (0, 9)**
Number of children with each genotype, median (90% central range) 4 (1,36)* 13 (1,48) 1 (0, 36)**
*Omitting the 5 most frequent alleles
** Omitting the 4 most frequent alleles
doi:10.1371/journal.pntd.0004582.t002
Table 3. Proportion of P vivaxMS16 genotypes observed in different intervals by the interval first seen*.
Interval
N genotypes 1 2 3 4 5 6 7 8 9
1 142 100% 22% 11% 12% 7% 4% 9% 5% 5%
interval 2 255 100% 15% 12% 13% 7% 8% 7% 5%
ﬁrst 3 230 100% 20% 12% 7% 10% 6% 3%
observed 4 227 100% 19% 8% 4% 6% 3%
5 232 100% 21% 11% 11% 6%
6 219 100% 16% 11% 6%
7 244 100% 12% 9%
8 186 100% 16%
9 102 100%
*In 143 children with at least one visit at each routine time-point. The ﬁrst interval includes the ﬁrst routine time-point only (ie no illness visits).
doi:10.1371/journal.pntd.0004582.t003
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[33]. The estimated seasonal pattern for P falciparum was averaged and extended to cover time
before the start of the cohort follow-up (Fig 2b).
The estimates for β1, which multiplies the P falciparum seasonality to give the incidence of P
vivax primary infections, for MS16 suggests that children in this cohort experience a mean of
11.5 (10.5,12.3) primary infections per year (Table 4). The estimates of primary infection were
lower formsp1F3 than for MS16 reflecting downward biases because superinfections with the
same allele do not contribute to the estimate (when very frequent alleles are included) or because
a substantial proportion of infections are excluded (when frequent alleles are excluded).
Bednet use was associated with a decrease in primary infections. Transmission intensity is
known to vary with village of residence in this study area, with a smaller village called Sunuhu
having a slightly higher transmission intensity compared to Ilaita [13]. This was also apparent
in our analysis.
The estimated incidence of relapse by time from primary infection, produced by β2 and the
lognormal distribution, implies that the mean number of relapses per primary infection is esti-
mated to be 4.3 (4.0, 4.6) using MS16. This estimate is consistent with other estimates [4,34],
allowing for some relapses to be unobserved if they occur when a blood-stage infection by the
same genotype is already present. The estimates frommsp1F3 for relapses are higher when all
alleles are included (probably as a result of re-infection with the same genotype), but similar
when the more frequent alleles have been omitted.
Since there were high levels of treatment in the cohort, we were unable to estimate the dura-
tion of blood-stage infection. We substituted estimates from data from malaria therapy in non-
immune adults in the models to ensure identifiability. A sensitivity analysis indicated that spec-
ifying a higher clearance rate would lead to higher estimates for the incidence rates. A higher
clearance rate of 2 per two-month interval, equivalent to a mean blood-stage infection duration
of 30 days, resulted in an estimated incidence of primary infections of 13.3 (11.9,14.2) per year
for a three-year old girl compared to 11.5 (10.5, 12.3) with the clearance rate set at 0.8 from
malaria therapy data; the mean number of relapses per primary infection was 5.9 (5.6, 6.2)
compared to 4.3 (4.0, 4.6).
Age was accounted for via body surface area for primary infections. Including an effect of
age on the incidence of relapse did not substantially change the estimates. The ratio for the
Fig 2. Estimated seasonal pattern of P falciparum infections (a) estimated pattern during study follow-
up (b) seasonal pattern extended to time preceding the study period.Circles (a): estimated seasonal
pattern of P falciparum infections (95%CI) during the study period. Solid line (b): inferred seasonal pattern of
P vivax primary infections during the study period. Dashed line (b): assumed seasonal pattern of P vivax
primary infections prior to the study period.
doi:10.1371/journal.pntd.0004582.g002
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incidence of relapses in children 36 months and over compared to under 36 months was esti-
mated to be 1.17 (1.04, 1.30) for MS16, adjusting for relapses within 5 months of the primary
infection and 6–16 months lead to a more complicated picture (0.95 (0.82, 1.11) and 1.65 (1.36,
2.00) respectively). These effects are consistent for MS16 andmsp1F3 and are significant but
relatively small and do not substantially alter the overall shape of the distribution. They are
also difficult to interpret as, while there could be a true age effect, there could also be compen-
sation for residual confounding with body surface area approximations or assumptions about
seasonality.
We attempted to adjust the P vivax incidence of relapse for the presence of a P falciparum
fever, any malaria fever, or any fever, in the previous interval. Unfortunately, the two month
intervals were too long relative to the two week time period of the hypothesis [4] and the results
were difficult to interpret.
The estimated incidence of relapse by interval since primary infection is shown in Fig 3a
using the estimates for MS16. The estimated incidence of relapses for a given number of inter-
vals following the primary infections shows lags in the seasonal pattern (Fig 3b). The total inci-
dence of relapse per interval is obtained by summing the relapses falling in each interval (Fig
3c). The pre-study period acts as a warm-up period and our interest lies in the study period
Table 4. Parameter estimates and 95% confidence intervals for the P vivaxmodel.
MS16 all msp1F3 alleles msp1F3 omitting 4 most common alleles
log likelihood 21431.2 14284.6 7761.7
β1: Factor for primary infection* 0.015 (.014, 0.016) 0.013 (0.012,0.015) 0.010 (0.008, 0.011)
Derived from the estimate for β1: the incidence of primary infection/year per for a 3 year old child for all genotypes (as a mean over the seasonal
ﬂuctuations over one year):
11.5 (10.5,12.3) 5.4 (4.9,6.4) 4.1 (3.1,4.6)
Covariates for the incidence of primary infection
Incidence rate ratio for bednet use 50% compared to <50%** 0.70 (0.63, 0.77) 0.74 (0.66, 0.84) 0.67 (0.56, 0.79)
Incidence rate ratio for Sunuhu compared to Ilaita 1.16 (1.04, 1.28) 1.07 (0.94, 1.20) 1.05 (0.89, 1.23)
β2: Ratio of incidence of relapses to ﬁxed pattern f(x) 37.2 (35.5, 39.0) 72.8 (69.6, 76.0) 32.8 (30.3, 35.5)
Derived from the estimate for β2:
Incidence of relapse/2 months following an individual primary infection (β2 f(x)):
γ0 0.27 0.52 0.24
γ1 1.38 2.70 1.22
γ2 0.99 1.94 0.88
γ3 0.61 1.21 0.54
γ4 0.41 0.80 0.36
γ5 0.28 0.55 0.25
γ6 0.20 0.38 0.17
γ7 0.14 0.27 0.12
γ8 0.10 0.20 0.09
Mean number of relapses per primary infection***:
4.3 (4.0,4.6) 8.3 (8.0,8.8) 3.7 (3.4,4.1)
*The estimates for P falciparum excluded the most frequent alleles and were scaled, and so this constant cannot easily be interpreted as a comparison
between the incidence of P vivax and P falciparum infections
** Bednet use was assumed to apply to both the pre-study and study periods
Analysis based on 243 children present at six or more routine time-points
*** Relapses may occur when a blood-stage infection from the same genotype is present or during the prophylactic period and so this is not necessarily
the number of distinct blood-stage infections
doi:10.1371/journal.pntd.0004582.t004
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itself. Relapses contribute substantially to the force of blood stage infection with the peak inci-
dence of relapse falling in the two month interval after that of primary infection. The propor-
tion of the force of blood-stage infections contributed by primary infections and relapses (Fig
3d) is seasonal, with relapses contributing between 71% and 90% of the total.
Transforming the estimated parameters into the force of blood-stage infection experienced
by a three year old child, we estimate the total to be approximately 50 per year at risk using
MS16 andmsp1F3 including all alleles. The molecular force of blood stage infection for P vivax
in this population has been previously estimated using MS16 as 13.8 (12.8, 14.8) blood-stage
infections per child per year-at-risk [14]. Our estimates are substantially higher, and this is
expected since we allow for detectability, the possibility of infections being acquired and cleared
between the two monthly routine time-points, for multiple relapses per two month interval,
Fig 3. Predicted P vivax relapse and primary infection for a three-year-old girl. (a) Estimated incidence
of relapse per infection by two month interval from the primary infection. (b) Estimated incidence of primary
infection and of relapses subsequent to primary infections one, two and six intervals earlier. Red circles: The
incidence of primary infections prior to (dotted line) and during (solid line) the study period. Blue lines: The
incidence of relapses subsequent to primary infections occurring one (light blue triangles), two (mid-blue
squares) and six (dark blue diamonds) intervals earlier. (c) Estimated force of blood-stage infection from
primary infections and relapses. Red circles: primary infections, blue diamonds: relapses. Shaded area is the
warm-up period prior to the study, unshaded area is the study period itself. (d) Estimated proportion of the
force of blood-stage infection from primary infections and relapses during the study period. Red triangles:
primary infections, blue diamonds: relapses. The predictions are for a three-year old girl in Ilaita village with
no ITN use using the results for MS16.
doi:10.1371/journal.pntd.0004582.g003
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and relapses occurring when blood-stage infections by the same genotype are already present.
The incidence of distinct blood-stage infections would be substantially lower.
Discussion
We have estimated the contribution and seasonality of primary infections and relapses by fit-
ting a model of the dynamics of P vivax infections to data from a cohort of children in Papua
New Guinea.
The seasonality of relapses may have implications for the timing of control strategies, as
recently suggested [35]. Mass drug administration with primaquine to clear the hypnozoites
would avert the greatest number of relapses if given after the peak transmission season. How-
ever if given together with a blood-stage drug with the aim of hitting hardest when onward
transmission is lowest, then the dry season may be most appropriate.
These findings aid the interpretation of estimates from two cohort studies conducted in
neighbouring regions in Papua New Guinea. In an initial study by Betuela et al [36], children
aged one to five years who received primaquine showed a 44% reduction in the time to reinfec-
tion compared to children who did not receive primaquine. This is substantially less than our
model would predict for the same period of the year (approximately 83% for April to July).
Together with the very rapid recurrence of P. vivax infections in the primaquine arm (median
30 days), this suggests the treatment used in that study (artesunate plus primaquine 0.5mg/kg/
d for 14 days) had poor efficacy in removing all hypnozoites in these children. Robinson et al
[37] randomized children between 5 to 10 years of age to a highly efficacious anti-hypnozoite
treatment of chloroquine, arthemeter-lumefantrine plus either primaquine (20d, 0.5 mg) or
placebo. This trial demonstrated an 83% reduction in risk of recurrent parasitaemia in children
that received the primaquine, leading to estimates of the numbers of relapses associated with
each primary infection similar to those of the present analyses. The Robinson et al cohort were
given liver-stage treatment in August. Our analysis suggests that the relative contribution of
relapses to the force of blood-stage infection is greatest during this time with a value of 90%.
Our results predict that had the study started in February, the proportion contributed by
relapses would be 21% lower. Further studies also support a substantial contribution of relapses
to blood-stage infection in parasites originating from this region [38,39].
The similarity of the results by Robinson et al [37] and the present study lends weight to the
findings. The approaches are different but complementary: the primaquine study is a powerful
and direct design, but can suffer from drug failure especially in participants with mutations in
the CYP2D6 gene [40]. The analysis here can estimate the incidence of primary infections and
relapses avoiding the need for primaquine, over longer follow up periods and incorporating
seasonality.
We did not observe substantial differences in relapse by age in this cohort. A previous study
in the same cohort found that estimates of the force of molecular blood stage infection (mol-
FOB) were similar in different age groups [14]. There is little trend in parasite prevalence across
this age range but clinical episodes decreased substantially with age [13]. The rate of relapses
may be an inherent characteristic of parasites from Papua New Guinea, and not influenced by
host age or immune status. There is a need to investigate relapses in cohorts including older
children with greater acquired immunity.
We did not include recombination in the model. A recent whole genome analysis of three
consecutive relapses in a traveler infected in Sudan showed that the relapses were meiotic sib-
lings [12]. Recombination between genotypes with the same MS16 ormsp1F3 allele would not
affect the analysis. However recombination between genotypes with different alleles would
mean that there would be higher numbers of relapses per infection: the model would
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overestimate the incidence of primary infection and underestimate the incidence of relapse. If
every infection was comprised of two genotypes then there would be roughly twice as many
relapses per infection as estimated. Preliminary extensions to the model to take the frequency
of recombination into account required excessive computational power.
Systemic fevers, including those of P falciparum, have been associated with P vivax relapses
[4,5,41,42]. We were unable to investigate an association between P vivax incidence of relapse
for the presence of a P falciparum fever, or any malaria fever, or any fever, in the previous inter-
val (results section) with this study design. We also do not take into account potential interac-
tions between P falciparum and P vivax, or between P vivax genotypes: these are the subject of
further work.
We approximated the seasonality of P vivax primary infections with that of P falciparum.
This approximation appears to be reasonable for theWosera in Papua New Guinea, but ento-
mological data from the study site itself or further settings would provide additional support.
The cohort also ages over the follow-up period. It is possible that the estimates of seasonality
could be confounded by differential acquired immunity to P falciparum and P vivax pre-eryth-
rocytic immunity. However, this effect has been estimated to be small for P falciparum [43]. The
estimated seasonality could also be affected by the assumption that detectability is the same all
year round: detectability may be greater in the rainy season for the major allele when parasite
densities are higher but may be reduced for minority alleles as MOI increases. We assume that
the seasonal pattern was the same as during the study period in the years before the study,
which ignores variation in seasonality between years. We did not account for uncertainty in the
P falciparum seasonality when estimating the P vivax parameters. We did not attempt simulta-
neous estimation of P falciparum seasonality and the P vivax parameters: the computational
requirements for the P vivaxmodel alone were challenging. However a sensitivity analysis
showed that small changes in P falciparum seasonality did not alter the conclusions for P vivax.
We were unable to estimate the natural clearance rate of untreated infections in this cohort
since antimalarial treatment was frequent. High levels of treatment have also been described
elsewhere in Papua New Guinea [44]. We substituted estimates from data from malaria therapy
in non-immune adults in the models to ensure identifiability. Fixing the value of the natural
clearance rate affects the estimates for the incidence of primary infection and relapse. A sensi-
tivity analysis indicated that specifying a higher clearance rate would lead to higher estimates
for the incidence rates. Preliminary analyses of other cohorts in Papua New Guinea have sug-
gested a shorter duration than that observed in malaria therapy patients. We also adopted an
exponential distribution for simplicity of the model. We recognize that this has been shown to
be incorrect for P falciparum [6,45] however the frequency of treatment does mean that
assumptions about the distribution of the duration of infections are unlikely to be critical.
We based our model on the frequency of genotype patterns observed, following previous
models of P falciparum [6,8,9]. The development of the model was driven by the biology of P
vivax and the need to include covariates and account for missing timepoints. The probabilities
of the observed patterns must be calculated for each combination of age, ITN use, treatments
administered, village and missing timepoints. Since these combinations refer frequently to only
one child in the study, the observed probabilities must be calculated for each child. As a conse-
quence, the computational demands are high. However this allows more flexibility and future
models could move farther away from patterns based on fixed intervals to continuous time.
Despite the limitations, the current model is suitable for the analyses shown here. To our
knowledge, this is the first time the contributions have been teased out in an endemic setting
without the use of primaquine.
The prevalence of P vivax is usually considered to be less seasonal than that of P falciparum.
In this paper, we have shown that this is composed of the different seasonal patterns of primary
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infections and relapses. Our analysis supports a substantial contribution of relapses to the force
of blood-stage infection in Papua New Guinea underscoring the need for effective intervention
strategies against liver-stage parasites.
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